ArticleMycopathologia2025
Prevalence of Candida and Other Yeasts in Vulvovaginal Infections during Pregnancy: A 10-Year Serbian Survey.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- VaginalJournal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Candida is a common and harmless component of the vaginal microbiota, present in approximately 50% of women of reproductive age. In specific conditions like pregnancy, Candida may cause chronic or recurrent infections which significantly impair quality of life. Additionally, due to the possibility of vertical transmission, it may lead to life-threatening infections in newborns. Timely screening, suspicion and identification of the causative agent are critical determinants of patient outcomes. Candida albicans (CA) remains the most prevalent species, but other non-albicans Candida (NAC) species and other non-Candida yeast (NCY) also play an important role in vulvovaginal infections. Due to the lack of precise local epidemiological data, this study aimed to determine the 10-year prevalence of CA, NAC and NCY species (spp.) in symptomatic pregnant women in Serbia using identification Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) for species identification. The total of 2,142 cases were examined (2013-2023) and the laboratory positivity was 48.3% (n = 1,035). The prevalence of CA, NAC and NCY were 74%, 23% and 3%, respectively. Biochemical and proteomic identification methods showed 100% concordance for CA, C. krusei (Pichia kudriavzevii), C. kefyr (Kluyveromyces marxianus), C. lusitaniae (Clavispora lusitaniae), and C. zeylanoides (Pichia norvengensis). Biochemical misidentification was observed for C. tropicalis (Lodderomyces sp.), C. glabrata (Nakaseomyces glabrata), and Saccharomyces cerevisiae. A global trend highlights the importance of renamed and reclassified yeast species in vaginal infections, supporting the reconsideration of the current disease name VVC in favor of the term vulvovaginal yeast infection (VYI). The prevalence of emerging NAC and NCY species is increasing but remains underestimated. There is a need for new laboratory diagnostic guidelines to enable timely and accurate identification, as this is crucial for guiding appropriate treatment and improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.